Home
About Us
Products and Services
Healthcare Professionals
Non-Healthcare Professionals
Guidelines
News
Contact Us
IMAGINE...
Frequently Asked Questions
Product Support
20th February 2008
Study suggests T-SPOT®.TB response declines with anti-TB treatment
29th October 2007
Oxford Immunotec completes $40M financing
09th October 2007
Study results confirm T-SPOT®.TB is cost-effective in TB control programmes
Oxford Immunotec is developing novel products based on its patented T-SPOT technology, opening new ways to diagnose and monitor infection and disease. The development of our lead product, T‑SPOT.TB is a major advance in the fight against the global resurgence of tuberculosis.
T‑SPOT.TB
T‑SPOT.TB is a revolutionary in vitro diagnostic
that measures T cells specific to Mycobacterium tuberculosis
(MTB) antigens. Based on the pioneering T-SPOT technology, it was developed
for diagnosing both latent TB infection and TB disease in humans. T-SPOT.TB sets
new clinical standards of sensitivity and reliability, particularly in
the immunocompromised.
Find out more